Glaukos Corp GKOS

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that operates globally. It focuses on developing treatments for corneal disorders, glaucoma, and retinal diseases. Incorporated in 1998, Glaukos has its headquarters in Laguna Hills, California.

Glaukos was a pioneer in the field of micro-invasive glaucoma surgery (MIGS), developed as an alternative to traditional glaucoma treatment. The company's products include the iStent, the iStent inject, and the iStent inject W, all micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through MIGS. To treat corneal disorder and keratoconus, Glaukos also offers bio-activated pharmaceutical therapy. The company's products are marketed through both a direct sales network and through distributors around the world.

Trading on the NYSE, Glaukos is listed under the ticker GKOS. In addition to its existing products, Glaukos also has a pipeline of surgical devices, implantable biosensors, and sustained pharmaceutical therapies in development. Products under development include the iStent Infinite to treat refractory glaucoma, iStent SA to treat mild-to-moderate glaucoma pseudophakic, and iDose TR, which is a targeted injectable implant that delivers therapeutic levels of medication for glaucoma treatment.

Keep up to date with the latest news and GKOS share price updates by adding it to your virtual eToro portfolio.